Constance Keyserling
Direttore operativo presso ABIONYX PHARMA
Posizioni attive di Constance Keyserling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ABIONYX PHARMA | Direttore operativo | - | - |
| Corporate Officer/Principal | - | - |
Storia della carriera di Constance Keyserling
Precedenti posizioni note di Constance Keyserling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
| ESPERION THERAPEUTICS, INC. | Direttore operativo | - | - |
| Parke, Davis & Co. LLC | Corporate Officer/Principal | - | - |
QuatRx Pharmaceuticals Co.
 QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - | - |
Formazione di Constance Keyserling
| Harvard University | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Francia | 2 |
Posizioni
| Corporate Officer/Principal | 4 |
| Chief Operating Officer | 2 |
| Graduate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ABIONYX PHARMA | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
| Parke, Davis & Co. LLC |
- Borsa valori
- Insiders
- Constance Keyserling
- Esperienza
